Title: Individualised incretin-based treatment for type 2 diabetes
Abstract: Type 2 diabetes is treated by a stepwise approach, starting with lifestyle changes at early stages (enforced by structured education for patients), combined with one or several glucose-lowering agents. Because of the progressive nature of the disease, an increasing number of glucose-lowering drugs have to be used with advancing diabetes duration.1 In The Lancet today, Richard Bergenstal and colleagues2 report the results of DURATION-2, comparing exenatide once weekly with either sitagliptin (an inhibitor of dipeptidyl peptidase-4) or pioglitazone (a thiazolidinedione), and Michaela Diamant and colleagues3 report the results of DURATION-3, comparing exenatide once weekly with insulin glargine titrated to predefined fasting glucose targets.
Publication Year: 2010
Publication Date: 2010-08-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 14
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot